A new “Training” tab has been added to the ODANO Intranet. In Training you can access the new ODANO education modules. They cover topics including:
Module 1 – Drug Access Navigation An Overview.
Module 2 – How Drug Access Works in Canada.
Module 3a – Navigating Drug Plans & Insurance (Private).
Module 3b – Navigating Drug Plans & Insurance (Public).
Module 4 – Pharmaceutical Sponsored Programs.
Module 5 – Putting it all Together.
Module 6 – Case Load Management and Ethics
Also, the new ODANO by-laws have been added in the Resources section for easy access to all members of the organization. If you’re unable to open the link in Resources, the by-laws are also accessible in the Files section.
Starting July 1, 2019, SADIE will be available to all Ontario physicians and nurse practitioners.
The development of SADIE has been very complex. The ministry has been focusing on the functionality that will deliver the highest value for patients/prescribers and the ministry first, ensuring those are successfully delivered before moving on to other items.
As a result, the ministry is delivering SADIE in a series of iterations, beginning with the prescriber portal. The SADIE portal allows prescribers to research criteria, complete requests using criteria-based forms for some drugs and generic forms for all others, and to be able to submit the request to the Exceptional Access Program. Because SADIE helps ensure that requests are properly completed, the turnaround times for requests submitted through SADIE have been significantly faster than the average for faxed in requests.
SADIE is work in progress: new capabilities and functions will be added as they are developed. Future releases of SADIE will be extending access to prescribers’ support resources so that they are able to perform many functions on behalf of the prescriber.
Submissions to the TEVA Compassionate Care Program no longer need to be mailed in. You can now send them by fax or email:
Fax to 1-800-387-4733
Or
Email to compassionate.program@tevacanada.com
Welcome to the new and improved www.odano.ca! A lot of work has gone into the new design. Features have been added, moved and others removed.
If you find anything that does not work properly, please let Alan Birch know. Like any new technology, there will be growing pains.
If you have any comments or suggestions, let Alan Birch know as well. The site is for Drug Access Navigators, so our goal is to make it work well for you all.
ODANO Team Leads
AstraZeneca is introducing a change to the financial assistance component of the PSP for new patients enrolled after 11:59 pm eastern time Monday, August 27th, 2018.
There is no change for patients enrolled prior to 11:59 pm eastern time Monday, August 27th, 2018. Patients enrolled as per the Health Canada notice of compliance will continue to receive TAGRISSO free of charge for as long as they require treatment with TAGRISSO, either via the PSP or public reimbursement.
New patients enrolled in the PSP after 11:59 pm eastern time Monday, August 27th, 2018 will be eligible for a co-payment towards the cost of the drug; they will not be eligible for drug free of charge.
Patients that have progressed on a first-line TKI and who have a T790M mutation validated test ORDERED prior to11:59 pm eastern time Monday, August 27th, 2018 will be eligible for drug free of charge.
▪ This includes patients who require multiple tests to confirm T790M mutation is present, e.g. negative ctDNA test followed by a tissue biopsy.
▪ Note that a confirmation email to Bayshore from the physician confirming a biopsy (tissue or ctDNA) has been ordered prior to 11:59 pm eastern time Monday, August 27th, 2018 is required.
All existing and new TAGRISSO patients will continue to have access to educational resources, dedicated nurse case managers and support services (e.g., nursing support, referral to patient organizations) to help them during their treatment. Patients accessing TAGRISSO through their private insurance plans will continue to do so.
For additional assistance with enrolling your patients, please contact the AstraZeneca Oncology Patient Support Program at 1-877-280-6208 (available Monday to Friday, from 8:00 AM – 8:00 PM EST).